

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 30, 2004

Signature:

Andrea Silverman
(Andrea Silverman)

Docket No.: SUPP-P01-007
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Graef et al.

Application No.: 10/824939

Filed: April 15, 2004

For: METHODS AND COMPOSITIONS FOR
ENHANCING NEURON GROWTH AND
SURVIVAL

Confirmation No.: 7564

Art Unit: N/A

Examiner: Not Yet Assigned

July 30, 2004

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the U.S. Patent and Trademark Office ("USPTO") is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR § 1.97(b)(3)).

A copy of each reference listed on the attached PTO/SB/08 is enclosed, except for U.S. patents and patent applications, since the USPTO has waived this requirement for applications filed after June 2003.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,


publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. SUPP-P01-007. A duplicate copy of this paper is enclosed.

Dated: July 30, 2004

Respectfully submitted,

By 
Gloria Fuentes
Registration No.: 47,580
ROPES & GRAY LLP
45 Rockefeller Plaza
New York, New York 10111-0087
(212) 497-3624
(212) 497-3650 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/824939
			Filing Date	April 15, 2004
			First Named Inventor	Isabella Graef et al.
			Art Unit	N/A
			Examiner Name	Not Yet Assigned
			Attorney Docket Number	SUPP-P01-007
Sheet	1	of	4	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA**	US-5,656,452	08/1997	Rao et al.	
	AB**	US-5,837,840	11/1998	Crabtree et al.	
	AC**	US-6,096,515	08/2000	Crabtree et al.	
	AD**	US-6,150,099	11/2000	Crabtree et al.	
	AE**	US-6,171,781	01/2001	Crabtree et al.	
	AF**	US-6,388,052	05/2002	Crabtree et al.	
	AG**	US-6,352,830	03/2002	Crabtree et al.	
	AH**	US-6,312,899	11/2001	Crabtree et al.	
	AI**	US-6,197,925	03/2001	Crabtree et al.	
	AJ**	US-6,165,787	12/2000	Crabtree et al.	
	AK**	US-6,140,120	10/2000	Crabtree et al.	
	AL**	US-6,063,625	05/2002	Crabtree et al.	
	AM**	US-6,054,436	04/2002	Crabtree et al.	
	AN**	US-6,046,047	04/2000	Crabtree et al.	
	AO**	US-6,043,082	03/2000	Crabtree et al.	
	AP**	US-6,011,018	01/2000	Crabtree et al.	
	AQ**	US-5,994,313	11/1999	Crabtree et al.	
	AR**	US-5,989,810	11/1999	Flanagan & Crabtree	
	AS**	US-5,871,753	02/1999	Crabtree et al.	
	AT**	US-5,869,337	02/1999	Crabtree et al.	
	AU**	US-5,834,266	11/1998	Crabtree et al.	
	AV**	US-5,830,462	11/1998	Crabtree et al.	
	AW**	US-5,523,227	06/1996	Bram and Crabtree	
	AX**	US-20040024725A1	02/2004	Crabtree et al.	
	AY**	US-20030056229A1	03/2003	Crabtree et al.	
	AZ**	US-20030049641A1	03/2003	Crabtree et al.	
	AA1**	US-20020173474A1	11/2002	Crabtree et al.	
	AB1**	US-20020042360A1	04/2002	Crabtree et al.	
	AC1**	US-20040024040A1	02/2004	Green et al.	
	AD1**	US-2004/0019052A1	01/2004	Garland et al.	
	AE1**	US-6,316,418	11/2001	Crabtree et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	BA	WO-93/04203A1	03/1993		
	BB	WO-94/15964A1	07/1994		
	BC	WO-95/02053A1	01/1995		
	BD	WO-95/08554A1	03/1995		
	BE	EP-1221483A1	07/2002		
	BF	EP-0722452B1	06/2002		
	BG	WO-02/24957A1	03/2002		
	BH	WO-01/36612A1	05/2001		
	BI	WO-00/30671A2	06/2000		

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824939
				Filing Date	April 15, 2004
				First Named Inventor	Isabella Graef et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	SUPP-P01-007
Sheet	2	of	4		

	BJ	WO-96/12796A1	05/1996		
	BK	WO-96/06111A1	02/1996		
	BL	WO-95/35501A1	12/1995		
	BM	WO-95/05389A1	02/1995		
	BN	WO-95/02684A1	01/1995		
	BO	WO-99/41258A1	08/1999		
	BP	WO-96/13613A1	05/1996		
	BQ	WO-94/18317A1	08/1994		
	BR	WO-00/38675A1	07/2000		
	BS	WO-00/21927A2	04/2000		
	BT	WO-98/16528A1	04/1998		
	BU	WO-01/09106A1	02/2001		
	BV	WO-02/062387A1	08/2002		
	BW	WO-01/74771A1	10/2001		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Clipstone and Crabtree, 1993, "Calcineurin is a key signaling enzyme in T Lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506," Ann. N.Y. Acad. Sci. 696:20-30		
	CB	Plunet et al., 2002, "Promoting Axonal Regeneration in the Central Nervous System by Enhancing the Cell Body Response to Axotomy," J. Neuro. Res. 68:1-6		
	CC	Goodnough et al., 2002, "Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists," FEBS Lett. 513:163-168		
	CD	Gao et al., 1999, "Genes regulating dendritic outgrowth, branching, and routing in <i>Drosophila</i> ," Genes & Dev. 13:2549-2561		
	CE	Lankford and Letourneau, 1989, "Evidence That Calcium May Control Neurite Outgrowth by Regulating the Stability of Actin Filaments," J. Cell Biol. 109:1229-1243		
	CF	Olave et al., 2002, "Identification of a polymorphic, neuron-specific chromatin remodeling complex," Genes & Dev. 16:2509-2517		
	CG	Neal and Clipstone, 2003, "A Constitutively Active NFATc1 Mutant Induces a Transformed Phenotype in 3T3-L1 Fibroblasts," J. Biol. Chem. 278(19):17246-17254		
	CH	Porter and Clipstone, 2002, "Sustained NFAT Signaling Promotes a Th1-Like Pattern of Gene Expression in Primary Murine CD4 ⁺ T Cells," J. Immunol. 168:4936-4945		
	CI	Plyte et al., 2001, "Identification and Characterization of a Novel Nuclear Factor of Activated T-cells-1 Isoform Expressed in Mouse Brain," J. Biol. Chem. 276(17):14350-14358		
	CJ	Leost et al., 2000, "Paullones are potent inhibitors of glycogen synthase-3 β and cyclin-dependent kinases 5/p25," Eur. J. Biochem. 267:5983-5994		
	CK	Smith and Skene, 1997, "A Transcription-Dependent Switch Controls Competence of Adult Neurons for Distinct Modes of Axon Growth," J. Neurosci. 17(2):646-658		
	CL	Graef et al., 2003, "Neurotrophins and Netrins Require Calcineurin/NFAT Signaling to		
Examiner Signature		Date Considered		

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824939
				Filing Date	April 15, 2004
				First Named Inventor	Isabella Graef et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	SUPP-P01-007

		Stimulate Outgrowth of Embryonic Axons," Cell 113(4):657-670	
	CM	Bush et al., 2004, "A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway," Proc. Natl. Acad. Sci. USA 101(9):2870-2875	
	CN	Boss et al., 1996, "Induction of NFAT-mediated Transcription by Gq-coupled Receptors in Lymphoid and Non-Lymphoid Cells," J. Biol. Chem. 271(18):10429-1-432	
	CO	Al-Daraji et al., 2002, "Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A," J. Invest. Dermatol. 118(5):779-88	
	CP	Francis et al., 2004, "A survival motor neuron:tetanus toxin fragment C fusion protein for the targeted delivery of SMN protein to neurons," Brain Res. 995(1):84-96	
	CQ	Rosenblad et al., 2000, "Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model," Exp. Neurol. 161(2):503-16	
	CR	Ye and Houle, 1997, "Treatment of the chronically injured spinal cord with neurotrophic factors can promote axonal regeneration from supraspinal neurons," Exp. Neurol. 143(1):70-81	
	CS	Bregman et al., 2002, "Transplants and neurotrophic factors increase regeneration and recovery of function after spinal cord injury," Prog. Brain Res. 137:257-73	
	CT	Stichel and Muller, 1998, "Experimental strategies to promote axonal regeneration after traumatic central nervous system injury," Prog. Neurobiol. 56(2):119-48	
	CU	Ebadi et al., 1997, "Neurotrophins and their receptors in nerve injury and repair," Neurochem. Int. 30(4-5):347-74	
	CV	Bulsara et al., 2002, "A new millenium for spinal cord regeneration: growth associated genes," Spine 27(17):1946-1949	
	CW	Markus and Snider, 2002, "Neurotrophic factors and axonal growth," Curr. Opin/ Neurobiol. 12(5):523-531	
	CX	Stoll and Muller, 1999, "Nerve injury, axonal degeneration and neural regeneration: basic insights," Brain Pathol. 9(2):313-325	
	CY	Yip and So, 2000, "Axonal regeneration of retinal ganglion cells: effect of trophic factors," Prog. Retin. Eye Res. 19(5):559-575	
	CZ	Himmelseher et al., 1997, "Effects of basic fibroblast growth factor on hippocampal neurons after axonal injury," J. Trauma 42(4):659-664	
	CA1	Monticelli and Rao, 2002, "NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription," Eur. J. Immunol. 32(10):2971-2978	
	CB1	Khavari et al., 1993, "BRG1 contains a conserved domain of the SW12/SNF2 family necessary for normal mitotic growth and transcription," Nature 366(6451):170-174	
	CC1	Wang et al., 1996, "Purification and biochemical heterogeneity of the mammalian SWI-SNF complex," EMBO J. 15(19):5370-5382	
	CD1	Wang et al., 1996, "Diversity and specialization of mammalian SWI/SNF complexes," Genes Dev. 10(17):2117-2130	
	CE1	Tessier-Lavigne and Goodman, 1996, "The molecular biology of axon guidance," Science 294:1123-1133	
	CF1	Beals et al., 1997, "Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction," Genes Dev. 11:824-834	
	CG1	Beals et al., 1997, "Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3," Science 275:1930-1934	
	CH1	Clipstone and Crabtree, 1992, "Identification of calcineurin as a key signalling enzyme in T cell activation," Nature 357:695-697	
	CI1	Crabtree, 1989, "Contingent genetic regulatory events in T lymphocyte activation," Science 243:355-361	
Examiner Signature		Date Considered	

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824939
				Filing Date	April 15, 2004
				First Named Inventor	Isabella Graef et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	SUPP-P01-007

	CJ1	Crabtree and Olson, 2002, "NFAT signaling: choreographing the social lives of cells," Cell 109(Suppl.):S67-79	
	CK1	Flanagan et al., 1991, "Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A," Nature 352:803-807	
	CL1	Goldberg et al., 2002, "Retinal ganglion cells do not extend axons by default: promotion by neurotrophic signaling and electrical activity," Neuron 33:689-702	
	CM1	Graef et al., 2001, "Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature," Cell 105:863-875	
	CN1	Graef et al., 2001, "NFAT signaling in vertebrate development," Curr. Opin. Genet. Dev. 11:505-512	
	CO1	Graef et al., 1999, "L-type calcium channels and GSK-3 regulate the activity of NFATc4 in hippocampal neurons," Nature 401:703-708	
	CP1	Hodge et al., 1996, "Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice," Immunity 4:397-405	
	CQ1	Hong et al., 2000, "Calcium signalling in the guidance of nerve growth by netrin-1," Nature 403:93-98	
	CR1	Kaplan and Miller, 2002, "Neurotrophin signal transduction in the nervous system," Curr. Opin. Neurobiol. 10:381-391	
	CS1	Klee et al., 1979, "Calcineurin: a calcium- and calmodulin-binding protein of the nervous system," Proc. Natl. Acad. Sci. USA 76:6270-6273	
	CT1	Ming et al., 1997, "cAMP-dependent growth cone guidance by netrin-1," Neuron 19:1225-1235	
	CU1	Ming et al., 2002, "Adaptation in the chemotactic guidance of nerve growth cones," Nature 417:411-418	
	CV1	O'Connor and Tessier-Lavigne, 1999, "Identification of maxillary factor, a maxillary process-derived chemoattractant for developing trigeminal sensory axons," Neuron 24:165-178	
	CW1	Serafini et al., 1996, "Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system," Cell 87:1001-1014	
	CX1	Serafini et al., 1994, "The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6," Cell 78:409-424	
	CY1	Shaw et al., 1988, "Identification of a putative regulator of early T cell activation genes," Science 241:202-205	
	CZ1	Stoichet et al., "Investigating a new entubulation strategy to overcome peripheral nerve injury," http://asme.pinetec.com/bio1999/data/pdfs/a0163445.pdf	
	CA2	Von Bernhardi and Bastiani, 1995, "Requirement of RNA synthesis for pathfinding by growing axons," J. Comp. Neurol. 357:52-64	
	CB2	Zheng et al., 2002, "Turning of nerve growth cones induced by localized increases in intracellular calcium ions," Nature 403:89-93	
	CC2	Zhu et al., 1998, "Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEK1," Cell 93:851-861	
	CD2	Oiwa et al., 2002, "Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease," Brain Res. 947(2):271-283	
	CE2	Mata et al., 2002, "Targeted gene delivery to the nervous system using herpes simplex virus vectors," Physiol. Behav. 77(4-5):483-488	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Application No. (if known): 10/824939

Attorney Docket No.: SUPP-P01-007

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 30, 2004
Date


Signature

Andrea Silverman
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant